{
  "case_id": "MN19-30932",
  "year": 2019,
  "patient_info": {
    "age_range": "31 to 40",
    "gender": "Female"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [],
  "complications": [],
  "symptoms": [
    "symptom flare-up",
    "joint tenderness"
  ],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "IVIG Therapy",
  "treatments_requested": [
    {
      "name": "Benlysta",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "treatments_tried_but_failed": [],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [],
  "is_denial_upheld": true,
  "issues_considered": [
    "medical_necessity"
  ],
  "other_issues": null,
  "guidelines_support": null,
  "guidelines_not_support": null,
  "guidelines_details": null,
  "soc_support": null,
  "soc_not_support": null,
  "soc_details": null,
  "study_support": true,
  "study_details": [
    {
      "study_name": "Phase III Belimumab Trials",
      "study_authors": "Not specified",
      "key_findings": "Serologically positive SLE patients responded favorably to treatment with belimumab plus standard of care therapy."
    }
  ],
  "key_questions": [
    "medical_necessity"
  ],
  "expedited": false,
  "rationale": "The requested service is not medically necessary for the treatment of the enrollee\u2019s medical condition. There is no documentation of any positive autoantibodies or low complement levels, indicating no evidence of active lupus requiring Benlysta.",
  "reviewer_credentials": "Board certified in Rheumatology, actively practicing, expert in the treatment of the enrollee\u2019s medical condition."
}